Idorsia will continue its open-label extension of the Phase 3 MODIFY trial to better determine if lucerastat, the company’s investigational oral therapy for Fabry disease, may be of benefit to patients’ kidneys and the heart. The decision comes despite the therapy having failed to outperform a placebo…
Avrobio is in the planning stages of a clinical trial to support a request for approval of AVR-RD-01 as a first-line gene therapy for people with  Fabry disease. This registration trial, which the company hopes to initiate in mid-2022 with U.S. Food and Drug Administration (FDA) agreement, will test the gene…
CANbridge Pharmaceuticals has entered a strategic collaboration and license agreement to gain global rights to LogicBio Therapeutics’ gene therapy candidates for rare diseases with limited treatment options. Under the agreement, CANbridge now owns worldwide rights to develop, manufacture, and commercialize gene therapy candidates for Fabry disease and Pompe…
Get regular updates to your inbox.